Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...

NHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy from April 2019. The new decision means that Afinitor will be ...

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Natco Pharma Ltd on Thursday said it has received approval from the US health regulator for its generic version of Everolimus tablets for oral suspension indicated for patients with tuberous sclerosis ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...